Sangivamycin is highly effective against SARS-CoV-2 in vitro and has favorable drug properties
Ryan P. Bennett(OyaGen (United States)), Jens H. Kuhn(National Institute of Allergy and Infectious Diseases)
Cited by 20
Related Papers
Ebola virus disease
|Nature Reviews Disease Primers|2020|634
Human, Nonhuman Primate, and Bat Cells Are Broadly Susceptible to Tibrovirus Particle Cell Entry
|bioRxiv (Cold Spring Harbor Laboratory)|2018|0